Alpha 1 Global

Our mission is to develop a collaborative global network of Alpha-1 patient leaders, physicians, and researchers, to increase awareness, detection, and access to care for Alphas around the world.


Respreeza announcement for Europe

Patients in Europe (Respreeza®) might experience a disruption of Respreeza® in the coming days. Respreeza® is CSL Behring’s prescription drug for the treatment of Alpha-1 …

Read More

Alfa1 Espana Receives “Best 2018 Respiratory Patient Project”

A hearty “Congratulations” to Alfa 1 España  for “Alfas en Camino” being selected as the Best 2018 Respiratory Patient Project by Separ De Pacientes Respiratorios! …

Read More

Grifols Affirms Commitment to Patients During Alpha-1 Awareness Month

November is Alpha-1 Awareness Month, and Grifols is proud to share its efforts to further increase Alpha-1 diagnosis rates and expand treatment options. Alpha-1 awareness matters. …

Read More

Mereo BioPharma and TAP Work Together in Clinical Study

Mereo BioPharma Group plc announced a collaboration with (and investment from) the venture philanthropy arm of the Alpha-1 Foundation, The Alpha-1 Project, Inc. (TAP) in …

Read More

Papers on Alpha-1 Research Published in the COPD Foundation Journal

The latest issue of the Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation (Volume 5, Issue 4 – 2018) features papers from presenters at …

Read More

Collaboration on New RNA Interference Drugs

(Reuters) – Arrowhead Pharmaceuticals Inc (ARWR.O) said on Thursday Johnson & Johnson (JNJ.N) would develop and market its gene-silencing Hepatitis B treatment and buy a …

Read More

Karen Erickson to Lead Operations in TAP

Summary: She has become one of the country’s leading advocates on patient-centered drug development and clinical trial design. The Alpha-1 Project (TAP) announces the appointment …

Read More

Gene-silencing Therapy (RNAi) is on the Move

“The recent announcements by Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals are excellent news for our patients. Both companies are developing therapies for the liver by ‘silencing’ …

Read More

Antibacterial Drug for Rare Lung Disease Gets Approved

The U.S. Food and Drug Administration (FDA) approved a new drug, Arikayce (amikacin liposome inhalation suspension), for the treatment of lung disease caused by a …

Read More

European Alpha-1 Research Collaboration – EARCO

A European Alpha-1 Research Collaboration (EARCO) has been formed to build a network of researchers and clinicians across Europe to improve research and treatment of …

Read More

Alpha-1 Around The Globe

Click on the country flags below to learn more about country specific contact and general information, access to care, and available resources

Join Our Newsletter

Subscribe to stay in touch with the latest in Alpha-1 Global